| Previous Close | 147.40 |
| Open | 146.70 |
| Volume | 4,728,955 |
| Avg. Volume (3M) | 7,317,118 |
| Market Cap | 220,754,083,840 |
| Price / Earnings (Forward) | 149.25 |
| Price / Sales | 6.89 |
| Price / Book | 8.31 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -9.40% |
| Operating Margin (TTM) | 0.99% |
| Diluted EPS (TTM) | -2.19 |
| Quarterly Revenue Growth (YOY) | 48.60% |
| Total Debt/Equity (MRQ) | 28.49% |
| Current Ratio (MRQ) | 1.96 |
| Operating Cash Flow (TTM) | 212.02 M |
| Levered Free Cash Flow (TTM) | -120.68 M |
| Return on Assets (TTM) | -3.22% |
| Return on Equity (TTM) | -11.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | BEIGENE | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.38 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| BEIGENE | 221 B | - | - | 8.31 |
| INNOCARE | 30 B | - | - | 3.19 |
| HENLIUS | 24 B | - | 26.46 | 8.48 |
| EVEREST MED | 19 B | - | - | 3.78 |
| ASCENTAGE-B | 17 B | - | - | 86.39 |
| INNOVENT BIO | 126 B | - | - | 8.83 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 4.57% |
| % Held by Institutions | 16.05% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |